

CURRICULUM VITAE

Aida Adlimoghaddam
dr.adlimoghaddam@gmail.com

EDUCATION:

Doctor of Philosophy (2010 – 2015)
Field of study: Biological Sciences (Molecular Biology)
University of Manitoba
Winnipeg, Manitoba, Canada

Master of Science (2005 – 2008)
Field of study: Medical Microbiology
Pasteur Institute of Iran, Tehran, Iran

Bachelor of Science (2001 – 2005)
Field of study: Microbiology
University of Tonekabon, Iran

WORK EXPERIENCES:

1. Research Associate (September 2018 – Present)
Fields of study: Neuroscience and Pharmacology
St. Boniface Hospital Research Centre
Division of Neurodegenerative Disorders (DND)
Laboratory of Synaptic Plasticity and Memory Dysfunction
Winnipeg, Manitoba, Canada
2. Senior Scientist
Field of study: Neuroscience
Mitrix Bio Inc. (January 2021– July 2021)
Pleasanton, California, USA
3. Postdoctoral Fellow (December 2015 –September 2018)
Fields of study: Neuroscience and Pharmacology
University of Manitoba
Department of Pharmacology and Therapeutics
Winnipeg, Manitoba, Canada
4. Co-Instructor of undergraduate and graduate level and required year-long pharmacology class)
(September 2017 – July 2019)
University of Manitoba
Department of Pharmacology and Therapeutics
Winnipeg, Manitoba, Canada

5. Visiting Scholar (May – July 2011, May – July 2013, and May – July 2014)
Learning and conducting Scanning Ion-selective Electrode Technique (SIET)
Department of Biological Sciences
McMaster University
Hamilton, Ontario, Canada
6. Laboratory instructor (undergraduate and graduate biological courses; September 2010 – September 2015)
Department of Biological Sciences
University of Manitoba
Winnipeg, Manitoba, Canada
7. Research Scientist (May 2009 –April 2010)
Faculty of Medicine
Tübingen University Hospital
Tübingen, Germany

TEACHING and SUPERVISION EXPERIENCE

- Co-instructor, Department of Pharmacology & Therapeutics, University of Manitoba, undergraduate and graduate Pharmacy/Nursing/Pharmacology students, PHAC 2100, PHAC 7134 – Series of lectures on epilepsy/antiepileptic drugs, drugs of abuse, performance-enhancing drugs (PEDs) (2017, 2019).
- Co-instructor, Department of Pharmacology & Therapeutics, University of Manitoba, undergraduate Pharmacology students, PHAC 4030 – Series of lectures on pre-clinical drug delivery using *Caenorhabditis elegans* as a model organism (2019).
- Invited Co-Instructor, Department of Biological Sciences, University of Manitoba, 3rd and 4th year Biological Sciences students, BIOL 4556 – Lectures on Molecular Biology Techniques for Eukaryotes (Fall semester 2014).
- Laboratory Instructor, Department of Biological Sciences, University of Manitoba, 1st and 2nd year Biological Sciences students, BIOL1010, 1020, 1030 - Principles of Biology, Biological Diversity, Function and Interactions (2010-2015) in the department of Biological Sciences at the University of Manitoba.
- Instructed, mentored, and supervised over 10 high school, undergraduate, and masters and doctoral students, for their thesis projects or volunteer projects.

TECHNIQUES/ SCIENTIFIC SKILLS:

In vitro and in vivo Pharmacology

Testing the effects of various drugs using primary mammalian cell culture (neurons, astrocytes, microglial cells, cardio cells), human cell lines (Caco2-BBE, FHS, HT29), invertebrate

(*Caenorhabditis elegans*), vertebrate (*Xenopus laevis*), and mammalian (3xTg, CRND8, C57BL/6 mice) model organisms.

Molecular Assays

DNA, RNA and protein extraction, mRNA isolation, cDNA, primer design, PCR, Real-time PCR q-PCR, RNAi based therapeutics, restriction enzyme digests, sequencing, cloning, optimization of reactions in PCR and DNA sequencing, gel-electrophoresis, ELISA, Western blotting, Mass Spectrometry, serology tests, collection, antigen and antibody detection, immunohistochemistry and immunocytochemistry, immunoprecipitation, U-plex, V-plex analysis, cytokine assay, gene knock-down techniques, ATP assay, tunnel assay, enzyme assays, metabolic rate and oxygen consumption measurements by Oxygraph and Seahorse, functional expression studies.

Cognitive and Behavioral assays

Cambridge neuropsychological test automated battery (CANTAB), Montreal cognitive assessment (MoCA), depression anxiety stress scale (DASS), morris water maze (MWM), novel object replacement, and novel object recognition.

Bioinformatics and Molecular Evolution

Management of DNA and amino acid sequence data (including submission of sequences to GenBank), utilization of NCBI databases (including BLAST search engines and the ORF finder program), generation of sequence contigs, alignment and analyses of DNA and amino acid sequences (using Sequencher and Se-AL; ClustalX), phylogenetic analyses (using Model Test, TCS, MrBayes, and PAUP), development and interpretation of RNA secondary structure models of rDNA (using the Mfold server).

Microscopy

Bright field microscopy, polarized microscopy, confocal/fluorescence microscopy, differential interference contrast microscopy, microtome and ultra-microtome sectioning, glass knife making (with "boat"), tissue fixation (glutaraldehyde and osmium tetroxide) and embedding (plastic – JB-4 methacrylate and Spurr/Epoxy resin), Grid preparation for transmission electron microscopy, cryosectioning, histological methods, fresh and fixed tissue staining.

Bioinformatics and extra skills

Management of DNA and amino acid sequence data (including submission of sequences to GenBank); utilization of NCBI databases (including BLAST search engines and the ORF finder program); generation of sequence contigs; alignment and analyses of DNA and amino acid sequences (using Sequencher and Se-AL; ClustalX); phylogenetic analyses (using Model Test, TCS, MrBayes, and PAUP); development and interpretation of RNA secondary structure models of rDNA (using the Mfold server). Experience in analytical Software applications such as SPSS, OriginPro, Graphpad, data management, documentation, report writing, grant writing.

RECOGNITION AND AWARDS:

- Research Grant Mitrix Inc (2021) \$1000
- Pharmacology and Therapeutics Postdoctoral Travel Award-University of Manitoba (2020) \$350

- Alzheimer's Drug Discovery Foundation (ADDF) Young Investigator Scholarship (USA Alzheimer's group) (2018)
- Research Manitoba Postdoctoral Fellowship (2016 – 2018) \$78,000
- Society for Neuroscience (SFN) (2017) \$500
- Alzheimer's Drug Discovery Foundation (ADDF) (2017) \$500
- Canadian Consortium on Neurodegeneration in Aging (CCNA)-CIHR (2017 – 2018) \$1800
- Canadian Conference Meeting (CAN) (2016 – 2018) \$500
- Seahorse Bioscience travel awards (2016) \$500
- Travel grants from Department of Biological Sciences, Faculty of Science, and Faculty of Graduate Studies, University of Manitoba (2010 – 2015) \$5000
- Research grant for doctoral candidates (DAAD scholarship)-Germany (September 2014 to June 2015) declined €10,000
- University of Manitoba Graduate Fellowship (UMGF) (2010 – 2014) \$64,000
- International Graduate Student Scholarship (IGSS) - University of Manitoba (2011–2012) \$2000
- Faculty of Graduate Studies (FGS) - University of Manitoba (2010 – 2011) \$1000
- International Graduate Student Entrance Scholarship (IGSES) - University of Manitoba (2010–2011) \$2000
- Spanish National Research Council (Consejo Superior de Investigaciones Científicas-CSIC) Spain (2009 –2013) declined €78,220
- Outstanding Graduate Student Award – Pasteur Institute of Iran (2007)

RADIO, TELEVISION, and YouTube INTERVIEWS:

- Alzheimer's Speaks Radio Talk Show – Interview by Lori Bey (2021)
- Dr. Aida Adlimoghaddam talks to Global new's Kahla Evans about the research she and her team are doing into neurodegenerative diseases at St. Boniface Hospital (2020).
<https://globalnews.ca/video/6636570/global-news-kahla-evans-talks-to-dr-aida-adlimoghaddam-live-at-the-st-boniface-hospital-mega-million-choices-lottery>
- This is Dr. Aida Adlimoghaddam, St. Boniface Hospital Research Centre
<https://www.youtube.com/watch?v=bPZobGj0cQ4> (2019)
- Alzheimer's Awareness Survey, The Health Report – CJOB 680 AM radio, Interview by Greg Mackling and Vince Barletta (2018).
- Alzheimer's Disease International (ADI) report, River City 360 Show, CJNU FM radio, Interview by Nolan Bicknell (2017).

CERTIFICATES:

- Foundations of Health Equities Research, Johns Hopkins Univ. Bloomberg School of Public Health (2021)
- Clinical Research Quality management (CQRM) (2020)
- Ethical Conduct for Research Involving Humans Course (TCPS 2: CORE) (2019)
- Protecting Human Subjects Research Online Training (PHRP) NIH (2019)
- Personal Health Information Act (PHIA) Training for Researchers (2019)
- Computer-based NIH Clinical Research training course (2019)

- Montreal Cognitive Assessment (MoCA) (2019)
- Clinical Dementia Rating (CDR)-Issuing authority Washington University School of Medicine in St. Louis (2019)
- Clinical and preclinical research ethics board (REB) (2016)
- Good Manufacturing Practices (GMP) Information session - Good manufacturing practices guide for drug products (GUI-0001) – University of Manitoba (2016)
- Certificate in what to do and not to do in teaching (2018)
- Certificate in Leadership – University of Manitoba (2016)

MEMBERSHIPS:

- The Society of Clinical Research Associates (SOCRA)
- Society for Neuroscience (SFN)
- Canadian Neuroscience Meeting (CAN)
- Canadian Conference on Dementia (CCD)
- Iran's National Elites Foundation (INEF)

PUBLICATIONS:

Published:

1. Davies DA*, **Adlimoghaddam A***, Albensi BC. 2021. Role of Nrf2 in synaptic plasticity and memory in Alzheimer's disease. 2021. Cells. DOI: 10.3390/cells10081884. ***First co-author**
2. **Adlimoghaddam A**, Albensi BC. 2021. The nuclear factor kappa B (NF-κB) signaling pathway is involved in ammonia-induced mitochondrial dysfunction. Mitochondrion. DOI: 10.1016/j.mito.2021.12.008.
3. Mostafizar M, Perez C, Snow WM, Djordjevic J, **Adlimoghaddam A**, and Albensi BC. 2021. Challenges with methods for detecting and studying the transcription factor nuclear factor kappa B (NF-κB) in the central nervous system. Cells. DOI: 10.3390/cells10061335.
4. Davies DA*, **Adlimoghaddam A***, and Albensi BC. 2021. Effect of COVID-19 on NF-κB and neurological manifestations of disease. Journal of Molecular Neurobiology. Special issue-MOLN-D-21-00377. ***First co-author**
5. Eshraghi M*, **Adlimoghaddam A***, Mahmoodzadeh A, Sharifzad F, Yasavo-li-Sharahi H, Lorzadeh Sh, Albensi BC, Ghavami S. 2021. Alzheimer's disease Pathogenesis: Role of autophagy and mitophagy focusing in microglia. International Journal of Molecular Sciences. DOI: 10.3390/ijms22073330. ***First co-author**
6. **Adlimoghaddam A**, Turner SR, and Albensi BC. 2020. FDA approved anti-cancer drug, nilotinib, increases energy metabolism in astroglia derived from 3xTg mouse model of Alzheimer's Disease. Journal of Aging and disease. DOI: 10.14336/AD.2020.0910.

7. Snow WM, Cadonic C, Cortes-Perez C, **Adlimoghaddam A**, Roy Chowdhury SK, Thomson E, Anozie A, Bernstein MJ, Gough K, Fernyhough P, Suh M, Albensi BC. 2020. Sex-Specific effects of chronic creatine supplementation on hippocampal-mediated spatial cognition in the 3xTg mouse model of Alzheimer's disease. *Journal of Nutrients*. DOI: 10.3390/nu12113589.
8. **Adlimoghaddam A**, Snow WM, Stortz G, Perez C, Goertzen AL, Ko JH, and Albensi BC. 2019. Regional hypometabolism in the 3xTg mouse model of Alzheimer's disease. *Journal of Neurobiology of Disease*. DOI: 10.1016/j.nbd.2019.03.008.
9. **Adlimoghaddam A**, Neuendorff M, Roy B, and Albensi BC. 2018. A review of clinical treatment considerations of donepezil in severe Alzheimer's disease. *Journal of CNS Neuroscience and Therapeutics*. DOI: 10.1111/cns.13035.
10. **Adlimoghaddam A**, Roy B, and Albensi BC. 2018. Future trends and the economic burden of dementia in Manitoba: Comparison with the rest of Canada and the world. *Journal of Neuroepidemiology*. DOI: 10.1159/000490414.
11. **Adlimoghaddam A**, Sabbir MG, and Albensi BC. 2016. Ammonia as a potential neurotoxic factor in Alzheimer disease. *Journal of Frontiers in Molecular Neuroscience* .9 (57), 1-27 DOI: 10.3389/fnmol.00057.
12. **Adlimoghaddam A**, O'Donnell M. J, and Weihrauch D. 2017. Sodium-hydrogen exchangers in *C. elegans*: Investigations towards their potential role in hypodermal H⁺ excretion, Na⁺ uptake, and ammonia excretion as well as acid-base balance. *Canadian Journal of Zoology*, 0008:4301.
13. Quijada-Rodriguez AR, **Adlimoghaddam A**, and Weihrauch D. 2017. Nitrogen excretion in nematodes, platyhelminthes and annelids. *Acid-Base Balance and Nitrogen Excretion in invertebrates: Mechanisms and strategies in various invertebrate groups with considerations of challenges caused by ocean acidification*. *Biology*. DOI: 10.1007/978-3-319-39617-0-5.
14. **Adlimoghaddam A**, O'Donnell MJ, Treberg JR, Kormish J, Merz D, and Weihrauch D. 2016. Ammonia excretion in *Caenorhabditis elegans*: Physiological and molecular characterization of the Rhr-2 knock-out mutant. *Comparative Biochemistry and Physiology Part A: Journal of Molecular & Integrative Physiology*. 31;195:46-54.
15. **Adlimoghaddam A**, Boeckstaens M, Marini AM, Treberg J, Brassinga AK, and Weihrauch D. 2015. Ammonia excretion in the non-parasitic soil nematode *Caenorhabditis elegans*: Mechanism and evidence of ammonia transport capability of an invertebrate Rh-protein, CeRhr-1. *Journal of Experimental Biology*, 218(5), 675-683 (**Highlighted in JEB**).
16. **Adlimoghaddam A**, Weihrauch D, and O'Donnell M. 2014. Localization of K⁺, H⁺, Na⁺ and Ca²⁺ fluxes across *Caenorhabditis elegans*: application of scanning ion-selective microelectrodes. *Journal of Experimental Biology*, 217, 4119–4122.
17. Cruz MJ, Sourial MM, Treberg JR, Fehsenfeld S, **Adlimoghaddam A**, and Weihrauch D. 2013. Cutaneous nitrogen excretion in the African clawed frog *Xenopus laevis*: Effects of high environmental ammonia (HEA). *Journal of Aquatic Toxicology*, 136–137C:1–12.

18. **Adlimoghaddam A**, Hedayati MH, Siadat SD, Ahmadi H, Nejati M, Vand yousefi J, and Norouzion D. 2008. Optimization of PCR conditions for detection of human Brucellosis from human serum samples, *Research Journal of Microbiology*, 3(5): 352–358, ISSN:1816–4935.
19. Hedayati MH, **Adlimoghaddam A**, Norouzion D, Tabbarae B, Ahmadi H, and Siadat SD. 2007. Improved diagnosis of Brucella In human serum samples by double PCR assay. *Iranian Journal of Medical Microbiology*, 1(3): 47–51, ISSN:1735–8612.

In progress:

1. Eshraghi M, Ahmadi M, Afshar S, **Adlimoghaddam A**, Lorzadeh Sh, Rezvani N, West R, Dastghaib S, Igder S, Naeimi Torshizi SR, Mahmoudzadeh A, Mokarram P, Madrakian T, Albensi BC, Los MJ, Ghavami S, Pecic S. 2021. Repurposing FDA-approved drugs as autophagy modulators in Alzheimer’s disease and related dementias. *Journal of Pharmacology & Therapeutics*. **Accepted with minor revision.**
2. Eshraghi M*, **Adlimoghaddam A***, Yasavoli H*, Sharifzad F, Mohammadzadeh A, Albensi BC, and Ghavami S. 2021. Network analysis of the role of autophagy in Alzheimer’s disease: Involvement of autophagosome maturation and autophagy Flux. Submitted to the *Journal of Autophagy*. ***First co-author**
3. **Adlimoghaddam A** and Albensi BC. 2022. Profiling and targeting of cellular bioenergetics: Lithium improves bioenergetics and biogenesis in the 3xTg mouse model of Alzheimer's disease. To be submitted to *Journal of Molecular Neurology*.

PRESENTATIONS:

1. **Adlimoghaddam A**, Turner SR, and Albensi BC. FDA approved anti-cancer drug, nilotinib, increases energy metabolism in astroglia derived from 3xTg mouse model of Alzheimer’s disease. 21st International Conference of Alzheimer's Drug Discovery Foundation (ADDF) October 2020. Virtual presentation.
2. **Adlimoghaddam A**. PET imaging of brain glucose metabolism in mouse model of Alzheimer’s disease. Invited talk by University of California (UCLA), Los Angeles, California, USA. Hosted by Dr. Elaine Reed. February 2020. Oral presentation.
3. **Adlimoghaddam A**, and Albensi BC. Effects of dietary flaxseed on memory and cognition of MCI patients. 12th Clinical Trials on Alzheimer's Disease (CTAD) December 2019. San Diego, California, USA. December 2019. Poster presentation.
4. **Adlimoghaddam A**, Turner SR, and Albensi BC. Using nilotinib, as a therapeutic approach for preventing Alzheimer’s disease. Canadian Neuroscience conference (CAN), Toronto, Ontario, Canada. May 2019. Poster presentation.
5. **Adlimoghaddam A** and Abensi BC. Effects of flaxseed on memory and cognition of Mild cognitive impairment patients. Faculty of health Science symposium. Winnipeg, Manitoba, Canada. April 2019. Poster presentation.

6. **Adlimoghaddam A**, Stortz G, Goertzen AL, Snow W, Ko JH, and Albeni BC. Regional brain hypometabolism is unrelated to amyloid plaque and tangle deposition in an Alzheimer's mouse model. The Canadian Consortium on Neurodegeneration in Aging (CCNA). Montreal, Quebec, Canada, October 2018. Oral presentation.
7. **Adlimoghaddam A**. Region-specific brain hypometabolism is unrelated to amyloid plaque and tangle deposition in an Alzheimer's mouse model. Department of Neurology and Neuroscience, Institute for Medical Science and Technology, Shahid Beheshti University, Tehran, Iran, July 2018. Invited talk by Iran's National Elites Foundation. Hosted by Dr. Mojtaba Zarei.
8. Weihrauch D, Zhouyao H, Hans S, **Adlimoghaddam A**, Durant A, and Donini A. AMTs (Ammonia Transporters) Expressed in Plants, Invertebrates and Fish. The Society for Experimental Biology (SEB). Florence, Italy, July 2018. Poster presentation.
9. **Adlimoghaddam A**, Snow W, Stortz G, Goertzen AL, Ko JH, Djordjevic J, Perez C, and Albeni. 18F-FDG PET imaging of brain glucose hypometabolism in the 3xTg mouse model of Alzheimer's disease. Canadian Neuroscience conference (CAN), Vancouver, British Columbia, Canada. May 2018. Poster presentation.
10. **Adlimoghaddam A**, Stortz G, Goertzen AL, Snow W, Djordjevic J, Perez C, Ko JH, and Albeni BC. Early detection of brain hypometabolism in the 3xTg mouse model of Alzheimer's disease. The Alzheimer's Association International Conference (AAIC). Chicago, Illinois, USA, July 2018. Poster presentation.
11. **Adlimoghaddam A**. Targeting Alzheimer cell mitochondria via an FDA approved anti-cancer drug, nilotinib, as a therapeutic approach. National Institute of Genetics and Biotechnology, Tehran, Iran, July 2017. Poster presentation.
12. **Adlimoghaddam A**, Turner RS, Cadonic C, and Albeni BC. Therapeutic targeting of mitochondria with the anti-cancer drug, nilotinib, in Alzheimer's disease. Canadian Conference on Dementia (CCD). Toronto, Ontario, Canada, November 2017. Poster presentation.
13. **Adlimoghaddam A**, Turner RS, and Albeni BC. Using nilotinib to improve mitochondrial function in Alzheimer's disease. Society for Neuroscience (SFN). Washington, DC, USA, November 2017. Poster presentation.
14. **Adlimoghaddam A**, Turner RS, and Albeni BC. Targeting Alzheimer cell mitochondria via nilotinib as a therapeutic approach. The Canadian Consortium on Neurodegeneration in Aging (CCNA). Toronto, Ontario, Canada, November 2017. Poster presentation.
15. **Adlimoghaddam A**, and Albeni BC. Hyperammonaemia triggers inflammatory responses in astroglial cells. Manitoba Neuroscience Network (MNN). Winnipeg, Manitoba, Canada. July 2017. Poster presentation.
16. **Adlimoghaddam A**, Turner RS, and Albeni BC. The anti-cancer drug, Nilotinib, enhances astroglial bioenergetics in Alzheimer's disease. Manitoba Neuroscience Network (MNN). Winnipeg, Manitoba, Canada. July 2017. Poster presentation.

17. **Adlimoghaddam A.** Exercise and Alzheimer's disease. Invited departmental talk. Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada, July 2017. Oral presentation.
18. Snow WM, Cadonic C, Perez C, **Adlimoghaddam A**, Djordjevic J, Gough KM, Suh M and Albeni BC. Creatine supplementation alters spatial cognition in the 3xTg mouse model of Alzheimer's disease in a sex-specific manner. CCNA Annual Partners Forum and Science Day, Toronto, Ontario, Canada. June 2017. Poster presentation.
19. Djordjevic J, Snow WM, Chowdhury SR, Cadonic C, **Adlimoghaddam A**, Perez C, Fernyhough P and Albeni BC. The onset of mitochondrial deficits is region-and sex-dependent in 3xTg mice. CCNA Annual Partners Forum and Science Day, Toronto, Ontario, Canada. June 2017. Poster presentation.
20. **Adlimoghaddam A.** NF- κ B in the mechanism of ammonia induced astrocyte swelling. Invited departmental talk. Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada, July 2016. Oral presentation.
21. **Adlimoghaddam A.** Ammonia and Alzheimer's disease. Invited talk. St. Boniface Hospital Research Centre, Winnipeg, Manitoba, Canada, January 2016. Oral presentation.
22. **Adlimoghaddam A**, O'Donnell M, and Weihrauch D. The potential involvement of Rh proteins in the ammonia excretory system in *Caenorhabditis elegans*. The society for integrative and comparative biology, West Palm beach, Florida, USA, January 2015. Oral presentation.
23. Treberg JR, Zacharias P, Quijada-Rodriguez A, Fehrmann F, **Adlimoghaddam A**, Diehl- Jones W, and Weihrauch D. Pre-exposure of luminal ammonia promotes an active ammonia excretion and changes in gene-expression patterns in the intestinal human cell line Caco-2BBE: does ammonia modulate intestinal transport. Canadian Nutrition Society, St. Johns, Newfoundland, Canada, June 2014. Oral presentation.
24. **Adlimoghaddam A**, O'Donnell M, Merz D, Kormish J, Weihrauch D. Function and localization of the primitive ammonia transporter (Rhr-2) in the non-parasitic soil nematode, *Caenorhabditis elegans*, Genomes to/aux Biomes, Montreal, Canada, May 2014. Oral presentation.
25. **Adlimoghaddam A.** Mechanisms and first evidence of the participation of ancient ammonia transporters in *Caenorhabditis elegans*. Invited talk. Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada, July 2013. Oral presentation.
26. **Adlimoghaddam A**, Brassinga AK, O'Donnell M, Merz D, Treberg J, and Weihrauch D. Investigation of the pH-regulation and ammonia excretion mechanism in the soil nematode, *Caenorhabditis elegans*, Canadian Society of Zoologists, Guelph, Canada, May 2013. Oral presentation.
27. **Adlimoghaddam A**, Brassinga AK, O'Donnell M, Merz D, and Weihrauch D. Investigation of the ammonia excretion mechanism in the non- parasitic nematode *Caenorhabditis elegans*. Prairie University Biology Symposium, University of Manitoba, Winnipeg, Canada, February 2013. Oral presentation.

28. **Adlimoghaddam A** and Weihrauch D. Ammonia excretion in the soil nematode *Caenorhabditis elegans* occurs via ammonia trapping across the hypodermis. Canadian Society of Zoologists, Mount Allison University, Sackville, Canada, May 2012. Poster presentation. Nominated for the best poster award.
29. **Adlimoghaddam A**. Molecular and physiological mechanism of nitrogen excretion in the soil nematode, *Caenorhabditis elegans*. Public Graduate Seminar of the Department of Biological Sciences, University of Manitoba, Winnipeg, Canada, November 2011. Oral presentation.
30. Hedayati MH and **Adlimoghaddam A**. Evaluation of enzyme-linked immunosorbent assay, standard tube agglutination and PCR methods for diagnosis of human brucellosis. 12th International Congress of Bacteriology and Applied Microbiology, Istanbul-Turkey, August 2008. Poster presentation.
31. Kamrani YY, Amanlou M, Yazdanyar A, **Adlimoghaddam A**, Ebrahimi SN. Potential antidiabetic and anti-oxidant activity of essential oil of *Zataria multiflora* leaves, 7th Joint Meeting of GA, AFERP, ASP, PSI & SIF, Athens, Greece, August 2008. Poster Presentation.
32. Ahmadi H. Tabaraiee B. Siadat SD. Poor mirza gholi F. Norouzian D. Nejati M. Hedayati MH. Mahmoodi K. SharifatSalmani A. Abbasi M. Karbasian M. **Adlimoghaddam A**. Immunological evaluation of Vi-vapsular polysaccharide of *Salmonella typhi* vaccine by serum bactericidal assay. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 2008. Poster presentation.
33. **Adlimoghaddam A**, Hedayati MH, Norouzian D, Tabaraie B, Ahmadi H, Siadat DS, Nejati M, and Mahmoodi K. Optimization of PCR Conditions for detection of human Brucellosis from human serum Samples. 2nd National Iranian Conference on Brucellosis, Tehran, Iran, September 2007. Oral presentation.
34. Abbasi M, Abaraei B, Siadat SD, Nejati M, Norouzian D, Ahmadi H, Salmani A Kayvan H, and **Adlimoghaddam A**. The comparison between electrophoretic patterns of extracted LPS from *Brucella abortus* by phenol and butanol method. The 1st national Iranian conference of applied microbiology, Tehran, Alzahra University, Tehran, Iran 2007. Oral presentation.
35. Ahmadi H and **Adlimoghaddam A**. A study of the production of IgA after the use of oral BCG encapsulated in alginate microspheres for DNA vaccine production. 9th Iranian Congress of Biochemistry & the 2nd International Congress of Biochemistry & molecular biology. University of Medical Science, Shiraz, Iran, November 2007. Poster presentation.
36. **Adlimoghaddam A** and Vand yousefi J. Immunological evaluation of LPS detoxified *brucella abortus*. The First Iranian Congress of Clinical Microbiology, Prof. Alborzi Clinical Microbiology Research Center-Shiraz University of Medical Sciences, Shiraz, Iran, May 2007. Poster presentation.
37. Ahmadi H, **Adlimoghaddam A**, Siadat SD, and Hedayati MH. Optimization of omp-31 Gene for detection of human brucellosis from human serum samples. 2nd National Iranian Congress of Brucellosis, Infectious diseases and tropical medicine research center-Shahid Beheshti University of Medical Sciences, Tehran, Iran, May 2007. Oral presentation.

38. Ahmadi H, Shapouri R, Tabaraie B, Siadat SD, Norozian D, Poormirzaghali F, Nejati M, Hedayati MH, and **Adlimoghaddam A**. Optimization of cultural condition of cell biomass production of brucella abortus S99. 15th Iranian congress on infectious diseases and tropical medicine, Tehran, Iran, December 2006. Oral presentation.